ENDRA Life Sciences Inc. - Rasio nilai perusahaan marang pendapatan NDRA

Simbol resmi perusahaan ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences production capacities are operating stably, while its cloud IT infrastructure is expanding without equipment depreciation. The company's EV/Sales ratio visualizes this basis, with the current value standing at 0.00. Revenue is projected through the implementation of TAEUS systems for liver analysis, which serve as replacements for MRI. The uniqueness of the thermoacoustic method allows for flexible pricing power regarding services for clinics.

ENDRA - Multiplikator EV/Sales NDRA (periode 23.11.2025 - 20.11.2026)

NDRA (ENDRA): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental perusahaan:NDRA (ENDRA Life Sciences)
Sampel barang ENDRA Life Sciences Inc

For ENDRA Life Sciences (NDRA), which seeks to capture the ultrasound diagnostics niche before medtech behemoths expand, this indicator is critical for distinguishing real growth from speculation. The metric is calculated as the ratio of enterprise value (market capitalization plus net debt) to annual revenue, allowing for an assessment of the cost per dollar of sales without distortions from debt load. By analyzing historical EV/Sales levels, an investor can determine whether the current asset premium is justified by the pace of technology commercialization.